Introduction: Varenicline helps people who smoke quit at rates 2-3 times greater than placebo. Currently, in the United States, varenicline is not available over the counter (OTC).
Aims And Methods: In this study, we assessed the safety and efficacy of 1 mg and 0.5 mg varenicline as an OTC medication for smoking cessation in comparison to placebo. This randomized, double-blind, placebo-controlled study was performed at two clinical sites in the United States of n = 313 people. The treatment period was 12 weeks. During the COVID pandemic, the protocol was modified to allow remote participation; verification of smoking status was via breath carbon monoxide levels for in-person visits and mailed urine cotinine kits for the remote participants.
Results: There was no difference in biologically confirmed continuous abstinence by condition between weeks 8 and 12; however, the odds of biologically confirmed point prevalence abstinence were higher for those in the 1 mg b.i.d. condition than for those in the placebo condition at week 12 (OR 3.39; 95% CI 1.49, 7.71), and were higher for those assigned to the 1.0 mg b.i.d. condition than the 0.5 mg b.i.d. condition at week 12 (OR 2.37; 95% CI 1.11, 5.05). Adverse events were modest, and as expected (vivid dreams and nausea in the medication conditions).
Conclusions: The results are suggestive that varenicline is safe and effective as an OTC medication.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ntr/ntae172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prostate artery embolization as an effective treatment for clinically significant prostate cancer‑related hemorrhage: A case report.
Exp Ther Med
February 2025
Department of Urology, Konstantopouleio-Patision General Hospital of Nea Ionia, 14233 Nea Ionia, Greece.
A 79-year old Caucasian male with metastatic hormone refractory prostate cancer and bilateral nephrostomy was admitted to the emergency department due to 4-day bloody urethral discharge, weakness and dizziness. The patient was treated with the luteinizing hormone-releasing hormone-antagonist and abiraterone acetate plus prednisone, dabigatran 150 mg bid (for atrial fibrillation and coronary heart disease) and 5-aminosalicylic acid for the management of mild ulcerative colitis. Imaging revealed bladder overdistention and blood analysis low levels of hematocrit (HCT) and hemoglobin (HGB) (HCT, 22%; HGB, 7.
View Article and Find Full Text PDFPopulation Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome.
Adv Ther
December 2024
Acadia Pharmaceuticals Inc., 12830 El Camino Real, Suite 400, San Diego, CA, USA.
Introduction: Oral trofinetide administered using a body weight-banded dosing regimen was approved in the US for the treatment of Rett syndrome (RTT) in patients aged ≥ 2 years. This approval was principally based on efficacy and safety findings of the phase 3 LAVENDER study in girls and women aged 5-20 years with RTT and extended to younger children aged 2-4 years with supporting data from the DAFFODIL study. Weight-banded dosing regimens were selected based on early clinical population pharmacokinetic (popPK) modeling and different scenario simulations.
View Article and Find Full Text PDFAddressing the challenges of integrating digital health technologies to measure patient-centred outcomes in clinical registries.
Lancet Digit Health
December 2024
Health Data Research, London, UK.
Longitudinal patient registries generate important evidence for advancing clinical care and the regulatory evaluation of health-care products. Most national registries rely on data collected as part of routine clinical encounters, an approach that does not capture real-world, patient-centred outcomes, such as physical activity, fatigue, ability to do daily tasks, and other indicators of quality of life. Digital health technologies that obtain such real-world data could greatly enhance patient registries but unresolved challenges have so far prevented their broad adoption.
View Article and Find Full Text PDFRole of intermittent hypoxic training combined with methazolamide in the prevention of high-altitude cerebral edema in rats.
Sci Rep
December 2024
Department of Neurosurgery, Neuromedicine Center, Beijing Shijitan Hospital, Capital Medical University, No. 10, Tieyi Road, Yangfangdian, Haidian District, Beijing, 100038, China.
Article Synopsis
- Intermittent hypoxia training (IHT) and methazolamide (MTZ) show limited effectiveness individually in preventing high-altitude cerebral edema (HACE), with few studies exploring their combined use.
- A rat model was developed to study the effects of IHT and MTZ on behavior, brain water content, pathology, and protein expression after exposure to hypobaric hypoxia and exhaustive exercise.
- The combination of long-course IHT and MTZ demonstrated the most significant improvement in spatial and memory function, brain pathology, and protein levels, indicating a potential effective approach for preventing HACE.
Multistep Removal System of Gaseous Toluene: Adsorption, Electrochemical, and Photolytic Treatments.
Chempluschem
December 2024
Centro de Investigación y Desarrollo Tecnológico en Electroquímica, S. C. (CIDETEQ)., Parque Tecnológico Querétaro s/n, San Fandila, 76730, Pedro Escobedo, Querétaro, México.
A large amount of atmospheric emissions result from various anthropogenic activities worldwide. Given the complexity of volatile organic compounds (VOCs) and their different adsorption capacities, redox potentials, and photolytic properties, an air purification system for the removal of VOCs that combines multiple physical processes was proposed in this study using toluene as an example. These processes include, in the first step, an adsorption treatment (AT) with activated carbon (AC), where toluene adsorption results from the insertion of aromatic rings (nonpolar groups) between the graphitic carbon planes, as demonstrated by the Raman spectroscopy; in the second step, electrochemical treatment (ECT) using TiO|Ti||SS-304 electrodes applying an electric field to accelerate the oxidation of toluene through the production of free radicals (⋅OH), hydroperoxyl radicals and benzyl groups, followed by the rupture of aromatic rings to generate aliphatic compounds and the consequent mineralization to CO, CO, and HO; in the third step, photolytic treatment (PT) with a 254-nm UV lamp for toluene degradation is used, which is influenced by the addition of radicals, such as ⋅OH or ⋅O , to transform toluene into either benzene or phenol.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!